Regulatory and Legislative Crackdown on PBMs and Vertical Integration
The highly integrated business model of modern managed care—which combines health insurance, Pharmacy Benefit Managers (PBMs), and retail/specialty pharmacies—is facing an escalating, multi-front regulatory, judicial, and legislative crackdown. While these conglomerates argue that vertical integration drives efficiency and lowers costs, regulators and lawmakers are increasingly presenting evidence that it enables massive generic drug markups and anti-competitive practices.
Bipartisan Congressional Pressure and the FTC Markup Findings
On January 22, 2026, the CEOs of the nation's largest healthcare conglomerates—including David Joyner of CVS Health and David Cordani of Cigna—faced a grueling, nine-hour bipartisan congressional grilling before the House Energy and Commerce and House Ways and Means Committees. Lawmakers focused heavily on the massive market concentration of the "Big Three" PBMs (CVS Caremark, Express Scripts, and OptumRx), which control approximately 80% of the U.S. prescription drug market.
During the hearings, Representative Alexandria Ocasio-Cortez (D-NY) cited a landmark Federal Trade Commission (FTC) staff report that exposed the extreme pricing power wielded by these integrated entities:
- Generics Marked Up by Thousands of Percent: The FTC found that the three largest PBMs marked up specialty generic drugs for cancer, HIV, and other severe conditions by thousands of percent at their own affiliated pharmacies.
- $7.3 Billion in Excess Revenue: Between 2017 and 2022, this markup practice generated more than $7.3 billion in revenue above estimated drug acquisition costs, keeping prescription prices artificially high for consumers and employers while padding corporate service margins.
Additionally, lawmakers target offshore PBM group purchasing organizations (GPOs), such as Cigna's GPO, Ascent Health Services, which is headquartered in Switzerland. Representative Erin Houchin (R-IN) highlighted findings that these offshore entities generated more than $50 million in revenue per employee, representing a highly lucrative, opaque channel for extracting manufacturer administrative fees and rebates.
Industry Defensive Pivots: Cigna's Rebate-Free Pharmacy Model
Under intense regulatory and public pressure, vertically integrated health plans are beginning to voluntarily restructure their pharmacy segments to ward off structural breakups.1
The most prominent example of this defensive pivot is Cigna's Evernorth division. In late 2025/early 2026, Cigna rolled out its newest rebate-free pharmacy benefit model, which aims to pass savings directly to consumers at the point of sale. During the January 22, 2026 congressional hearings, CEO David Cordani confirmed that Cigna’s newest pharmacy offering would accommodate direct-to-consumer low-cost drug models (such as Mark Cuban's Cost Plus Drugs) and count those purchases toward patient deductibles.
However, this transition away from opaque rebate-retention models is not financially free. Cordani acknowledged that the shift to the rebate-free pharmacy model would reduce Cigna's near-term earnings by up to $600 million, representing a tangible margin concession to ease regulatory heat.
Despite this, Cigna's consolidated financial performance remains highly resilient:
- TTM Revenue (as of August 24, 2026): $282.38B (+6.7% YoY).
- Earnings Trajectory: Cigna has delivered four consecutive quarterly earnings beats, reporting Q2 2026 EPS of $7.78 (vs. $7.58 est.) and quarterly operating income of $2.68B.
- Valuation: The stock trades at a highly attractive P/E ratio of 11.48 (with a market cap of $73.33B), as the market prices in Evernorth's ability to navigate regulatory shifts.
Similarly, CVS Health (CVS) is working to stabilize its Caremark division amidst retail pharmacy closures and Aetna's margin recovery, posting Q2 2026 revenue of $106.10B and beating earnings estimates at $2.58 per share (vs. $1.87 est.).
-
An instance of Opaque rebate retention collapses the moment regulators force transparent net-cost pricing. — It shows how PBMs are proactively shifting away from opaque rebate-retention models in response to mounting legislative and regulatory scrutiny. ↩︎